Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...

Neumora halted one trial of its depression drug navacaprant and paused a pair of late-stage studies as it tries to learn from ...

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

During the completed Phase 3 clinical trial, the 5-year survival rate of the target patient population increased to 73% when patients were treated with Multikine vs 45% for control patients who ...

The need for rescue therapy was three ... their clinical endpoints, obinutuzumab can induce greater B-cell depletion than other anti-CD20 antibodies, Furie explained. In a phase 2 trial, called ...

It noted that the trial is the first ever HPV16-positive head and neck cancer phase 3 clinical trial. EMV Capital shares closed up 1.1% at 44.48 pence on Friday afternoon in London. PDS Biotechnology ...

During the completed Phase 3 clinical trial, the 5-year survival rate of the target patient population increased to 73% when patients were treated with Multikine vs 45% for control patients who ...

The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single ...

Conventional histological analysis 30.8% (p=0.036 vs placebo) and 28.3% (p=0.065 vs placebo ... as a combination therapy.” The Phase 2b ICONA clinical trial was a 52-week randomized, double ...

The company's existence depends almost entirely on the outcome of the Phase 2 trial ... of clinical differentiation from GLP-1s or FGF21 analogs. With Pemvidutide estimated to be launched 3 ...